Pathology: mUC - L1 - all population; mUC - L1 - PDL1 positive;
mUC - L1 - all population | mUC - L1 - PDL1 positive | ||
DANUBE (DT vs C - all population), 2020 | DANUBE (DT vs C - PDL1>25%), 2020 | ||
durvalumab plus tremelimumab | 2 | T1 | T1 |
gemcitabine plus platin | 0 | T0 | T0 |